Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent i
about
Comparison of human immunodeficiency virus (HIV)-specific infection-enhancing and -inhibiting antibodies in AIDS patients.Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodiesAdditive Effects Characterize the Interaction of Antibodies Involved in Neutralization of the Primary Dualtropic Human Immunodeficiency Virus Type 1 Isolate 89.6Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization.Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variablesStoichiometry of antibody neutralization of human immunodeficiency virus type 1.Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines.Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usageNeutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1.An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades.Chemokine coreceptor usage by diverse primary isolates of human immunodeficiency virus type 1Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes.Identification of gp120 regions targeted by a highly potent neutralizing antiserum elicited in a chimpanzee inoculated with a primary human immunodeficiency virus type 1 isolateCross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope.Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjectsHigh prevalence of neutralizing activity against multiple unrelated human immunodeficiency virus type 1 (HIV-1) subtype B variants in sera from HIV-1 subtype B-infected individuals: evidence for subtype-specific rather than strain-specific neutralizMolecular typing of enteroviruses: current status and future requirements. The European Union Concerted Action on Virus Meningitis and EncephalitisNeutralization patterns and evolution of sequential HIV type 1 envelope sequences in HIV type 1 subtype B-infected drug-naive individuals.Superinfection by discordant subtypes of HIV-1 does not enhance the neutralizing antibody response against autologous virus.The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection.Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa.The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development.Genetic and neutralization sensitivity of diverse HIV-1 env clones from chronically infected patients in ChinaGenetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa.Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes.Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodiesNeutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization.Failure of a human immunodeficiency virus type 1 (HIV-1) subtype B-derived vaccine to prevent infection of chimpanzees by an HIV-1 subtype E strainA novel antibody-dependent cellular cytotoxicity epitope in gp120 is identified by two monoclonal antibodies isolated from a long-term survivor of human immunodeficiency virus type 1 infectionHuman immunodeficiency virus type 1 intersubtype (B/E) recombination in a superinfected chimpanzee.Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope.Multivariate analysis of human immunodeficiency virus type 1 neutralization dataFactors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection.Introduction and immunopathogenesis of acquired immune deficiency syndrome.
P2860
Q24538755-A6215DC7-8106-4201-A5A0-395239E03AF8Q24561905-1BE976ED-C34F-4ED2-ACDD-B5094C300098Q27469855-A6F09B79-66BF-4E76-8CAE-1463A1A1C3C2Q30423779-473E9B04-9117-494F-B0ED-9A009B5E4C99Q31016954-0F8B15FC-C382-458E-988E-D2CFAF4CA752Q31143293-5B891C73-4615-4A5C-B98E-221257B67705Q33272711-4BB11975-F24F-4B00-A7D2-656F785F3EEFQ33614495-BAB7F657-8899-4262-9EAF-B9DFA2280EB2Q33737656-5C18AA2B-E86A-43FA-AE00-6ED0E7656DC9Q33780524-445F60AF-DD46-498E-ADA9-FABCD471326CQ33782296-64839BF4-3421-4E7D-B62C-EC638177759DQ33783516-0D824D9F-5B78-47A5-BDAF-30D54DE40056Q33784679-6214CFA3-EE5D-43BE-9491-BB424E1BEA80Q33785473-C6DA74D1-017E-4761-BED0-1D797263DD2BQ33786049-F0839B58-DA17-45FF-9CD8-4B49D1226970Q33787329-9947B07E-9B65-404E-8336-2D6BFE95EE49Q33811940-BB44A72A-CE86-4F90-91C8-7137ED2D2E68Q33813526-BA7181B0-A8CB-460E-A798-F17C2025901FQ33842152-68692471-3785-409F-88BE-0AE46710EFC7Q33888559-AE04147E-3FA6-4BA3-92CB-3581C48A2FFBQ33920519-0B75F445-285C-41EE-A35E-F85B6EE1512FQ33992691-3616C3BC-9C2E-464B-B692-4699D301FAD2Q34085098-5716C41A-BFDA-40D6-8794-5A7B9BB91E35Q34312037-B316DB90-E910-4819-AF50-E6EC7B864AEBQ34317025-B54A9F82-C946-448A-A028-7014F3DA8C26Q34332009-56EE9A37-0EBA-4656-A31D-A1D9EA2770C1Q34342352-66D6B68B-8407-4BA9-BA47-46143B54F84FQ34391256-5A6362CF-3DF4-49F0-B18C-812BBC679817Q34800408-C78936B8-1448-4DB6-866F-2427A477F624Q35140032-E37DB8F1-489A-43F0-AFF9-3DC6D0792053Q35853750-3E6EEEB7-D920-44BE-AD52-B4E47C0BB007Q35857254-20F7F0DB-A84B-4DD4-AF7A-F8D683F3FFA7Q35872254-E5625C34-6669-434B-AA7C-3A54352A0C1FQ35872988-E37105BF-B3F4-466D-ADE7-7A3ED757FBC4Q35876233-2155146F-812F-40FB-8152-2805FAA522D0Q35896382-B4D6237C-F3E9-4C5F-857C-E6A54744797EQ36549107-F56119E7-D194-4EB3-A694-D170DAABF932Q36808080-FE6FE94E-7E10-4834-9AF8-CB8FFD111081Q37033294-CB323F99-67B5-48C3-BED7-E32B224B336EQ37084328-0D052E04-803D-40AB-B4E5-50A5A7F9D55A
P2860
Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent i
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Quantitative analysis of serum ...... or prevalent serum-dependent i
@ast
Quantitative analysis of serum ...... or prevalent serum-dependent i
@en
type
label
Quantitative analysis of serum ...... or prevalent serum-dependent i
@ast
Quantitative analysis of serum ...... or prevalent serum-dependent i
@en
prefLabel
Quantitative analysis of serum ...... or prevalent serum-dependent i
@ast
Quantitative analysis of serum ...... or prevalent serum-dependent i
@en
P2093
P2860
P1433
P1476
Quantitative analysis of serum ...... or prevalent serum-dependent i
@en
P2093
P2860
P304
P407
P577
1996-01-01T00:00:00Z